EV / EBITDA společnosti IMV
Jaká je hodnota metriky EV / EBITDA společnosti IMV?
Hodnota metriky EV / EBITDA společnosti IMV, Inc. je N/A
Jaká je definice metriky EV / EBITDA?
EV/EBITDA je podniková hodnota dělená EBITDA (zisk před odečtením úroků, daní, odpisů a amortizací). Měří nákladnost akcie a používá se k porovnání společností mezi sebou častěji než P/E ratio. Měří cenu, jakou investor zaplatí za pohyb hotovosti ve společnosti.
Price to earnings ratios are impacted by a company's choice of capital structure - companies which raise money via debt will have lower P/Es (and therefore look cheaper) than companies that raise an equivalent amount of money by issuing shares, even though the two companies might have equivalent enterprise values. A sample case is when a company with debt were to raise money by issuing shares of stock, and then used the money to pay off the debt, this company's P/E ratio would shoot up because of the increased number of shares - although nothing about the fundamental value of the business has changed. EV / EBITDA is unaffected by capital structure as enterprise value includes the value of debt, and EBITDA is available to all investors (debt and equity) as it excludes interest payments on that debt. It is ideal for analysts and potential investors looking to compare companies within the same industry.
EV / EBITDA společností v sektoru Health Care sektor na TSX ve srovnání se společností IMV
Čemu se věnuje společnost IMV?
IMV Inc. operates as a clinical-stage immuno-oncology company. The company develops a portfolio of therapies based on DPX its immune-educating technology platform for treatment of solid and hematological cancers. The company's lead drug candidate includes maveropepimut-S, a DPX-based immunotherapy that targets survivin-expressing cells that is Phase II clinical trials for diffuse large B cell lymphoma; ovarian cancer; and bladder, liver, and microsatellite instability high tumors, as well as in Phase I clinical trial for breast cancer. It also develops DPX-SurMAGE that is in Phase I clinical trial for bladder cancer; and DPX-COVID-19 and DPX-RSV for infectious diseases. The company was formerly known as Immunovaccine Inc. and changed its name to IMV Inc. in May 2018. IMV Inc. was founded in 2000 and is headquartered in Dartmouth, Canada.
Firmy s metrikou ev / ebitda podobnou společnosti IMV
- Hodnota metriky EV / EBITDA společnosti Primo Nutraceuticals je N/A
- Hodnota metriky EV / EBITDA společnosti Killi je N/A
- Hodnota metriky EV / EBITDA společnosti Nautilus Inc je N/A
- Hodnota metriky EV / EBITDA společnosti CPP Plc je N/A
- Hodnota metriky EV / EBITDA společnosti Lee Hing Development je N/A
- Hodnota metriky EV / EBITDA společnosti Blockmate Ventures je N/A
- Hodnota metriky EV / EBITDA společnosti IMV je N/A
- Hodnota metriky EV / EBITDA společnosti Great Atlantic Resources je N/A
- Hodnota metriky EV / EBITDA společnosti Paringa Resources je N/A
- Hodnota metriky EV / EBITDA společnosti Virios Therapeutics je N/A
- Hodnota metriky EV / EBITDA společnosti Asimilar Plc je N/A
- Hodnota metriky EV / EBITDA společnosti Sanbase je N/A
- Hodnota metriky EV / EBITDA společnosti Deep-South Resources je N/A